CA2448218A1 - Sustained release formulation - Google Patents
Sustained release formulation Download PDFInfo
- Publication number
- CA2448218A1 CA2448218A1 CA002448218A CA2448218A CA2448218A1 CA 2448218 A1 CA2448218 A1 CA 2448218A1 CA 002448218 A CA002448218 A CA 002448218A CA 2448218 A CA2448218 A CA 2448218A CA 2448218 A1 CA2448218 A1 CA 2448218A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- protein
- zinc
- kit
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract 53
- 238000013268 sustained release Methods 0.000 title claims 11
- 239000012730 sustained-release form Substances 0.000 title claims 11
- 238000009472 formulation Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 claims abstract 44
- 108090000623 proteins and genes Proteins 0.000 claims abstract 44
- 229910052751 metal Inorganic materials 0.000 claims abstract 17
- 239000002184 metal Substances 0.000 claims abstract 17
- 229920005862 polyol Polymers 0.000 claims abstract 10
- 150000003077 polyols Chemical class 0.000 claims abstract 10
- 238000000034 method Methods 0.000 claims 32
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 22
- 229910052725 zinc Inorganic materials 0.000 claims 22
- 239000011701 zinc Substances 0.000 claims 22
- 239000007788 liquid Substances 0.000 claims 16
- 239000001797 sucrose acetate isobutyrate Substances 0.000 claims 16
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 claims 16
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 claims 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 14
- 150000001768 cations Chemical class 0.000 claims 14
- 239000002904 solvent Substances 0.000 claims 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 12
- 239000011344 liquid material Substances 0.000 claims 10
- -1 threhalose Substances 0.000 claims 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 6
- 229930195725 Mannitol Natural products 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 239000000594 mannitol Substances 0.000 claims 6
- 235000010355 mannitol Nutrition 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims 4
- 239000012876 carrier material Substances 0.000 claims 4
- 150000004676 glycans Chemical class 0.000 claims 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 4
- 229960000367 inositol Drugs 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 150000002772 monosaccharides Chemical class 0.000 claims 4
- 239000005017 polysaccharide Substances 0.000 claims 4
- 229920001282 polysaccharide Polymers 0.000 claims 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 4
- 239000000600 sorbitol Substances 0.000 claims 4
- 102000018997 Growth Hormone Human genes 0.000 claims 2
- 108010051696 Growth Hormone Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 229940116342 acetylated sucrose distearate Drugs 0.000 claims 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims 2
- 229960002903 benzyl benzoate Drugs 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 150000002191 fatty alcohols Chemical class 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 150000004668 long chain fatty acids Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004962 physiological condition Effects 0.000 claims 2
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Abstract
A composition comprises a protein, a polyiol, and a metal. The protein is stabilized by the polyol and the metal, and is protected from denaturing when in contact with an organic solvent. The polyol may be a hydrocarbon containing two or more hydroxyl groups (-OH) bonded to carbon. The metal may be divalent.
Claims (83)
1. A composition, comprising:
a protein;
a polyol; and a metal cation.
a protein;
a polyol; and a metal cation.
2. The composition of claim 1, wherein said polyol is selected from the group consisting of a monosaccharide, a polysaccharide, glycerol, mannitol, sorbitol, inositol, and polyethylene glycol.
3. The composition of claim 1, wherein said polyol is selected from the group consisting of mannitol, threhalose, and polyethylene glycol.
4. The composition of any one of claims 1-3, wherein the mass ratio of polyol to protein is from 100:1 to 1:100.
5. The composition of any one of claims 1-3, wherein the mass ratio of polyol to protein is from 1:1 to 1:10.
6. The composition of any one of claims 1-5, wherein the metal cation is divalent.
7. The composition of any one of claims 1-6, wherein the metal cation is zinc.
8. The composition of claim 7, wherein the molar ratio of zinc to protein is from 1:1 to 100:1.
9. The composition of claim 7, wherein the molar ratio of zinc to protein is from 1:1 to 20:1.
10. The composition of claim 7, wherein the molar ratio of zinc to protein is from 1:1 to 10:1.
11. The composition of any one of claims 1-10, wherein the protein is selected from the group consisting of a growth hormone, insulin, and a growth factor.
12. The composition of any one of claims 1-11, further comprising a carrier material;
wherein the carrier material comprises a non-polymeric, non-water soluble liquid material having a viscosity of at least 5,000 cP at 37 °C
that does not crystallize neat under ambient physiological conditions.
wherein the carrier material comprises a non-polymeric, non-water soluble liquid material having a viscosity of at least 5,000 cP at 37 °C
that does not crystallize neat under ambient physiological conditions.
13. The composition of claim 12, wherein the liquid material is a stearate ester, a stearate amide, a long-chain fatty acid amide, a long-chain fatty alcohol, a long-chain ester, or a disaccharide ester.
14. The composition of claim 12, wherein the liquid material is acetylated sucrose distearate.
15. The composition of claim 12, wherein the liquid material is disaccharide acetate butyrate.
16. The composition of claim 12, wherein the liquid material is sucrose acetate isobutyrate.
17. The composition of any one of claims 1-16, wherein the composition has a viscosity less than 1000 cP at room temperature.
18. The composition of any one of claims 1-16, wherein the composition has a viscosity less than 200 cP at room temperature.
19. A method of administering a protein, comprising:
injecting the composition of any of claims 1-18 into a patient in need of said protein.
injecting the composition of any of claims 1-18 into a patient in need of said protein.
20. The method of claim 19, wherein less than 10% of the protein is released within 24 hours of administration.
21. The method of claim 19, wherein less than 0.2% of the protein is released within 24 hours of administration.
22. The method of any one of claims 19-21, wherein the percentage of the protein released within a 24 hour period is from 0.05% to 3%.
23. The method of any one of claims 19-21, wherein the percentage of the protein released within a 24 hour period is from 1 % to 3%.
24. A method of making a sustained release composition, comprising:
mixing a complex and a liquid carrier to form said sustained release composition;
wherein said liquid carrier comprises sucrose acetate isobutyrate; and wherein said complex comprises a protein, a polyol, and zinc.
mixing a complex and a liquid carrier to form said sustained release composition;
wherein said liquid carrier comprises sucrose acetate isobutyrate; and wherein said complex comprises a protein, a polyol, and zinc.
25. The method of claim 23, wherein said sustained release composition has a viscosity less than 1000 cP at room temperature.
26. The method of claim 23, wherein said sustained release composition has a viscosity less than 200 cP at room temperature.
27. The method of any one of claims 24-26, wherein the molar ratio of zinc to protein is from 100:1 to 1:1.
28. The method of any one of claims 24-26, wherein the molar ratio of zinc to protein is from 10:1 to 1:1.
29. The method of any one of claims 24-28, wherein said liquid carrier further comprises a solvent.
30. The method of claim 29, wherein said solvent is ethanol, benzyl benzoate, miglyol, propylene carbonate, or benzyl alcohol.
31. The method of any one of claims 29-30, wherein the ratio of sucrose acetate isobutyrate to solvent is from 50:50 w/w to 85:15 w/w.
32. The method of any one of claims 29-30, wherein the ratio of sucrose acetate isobutyrate to solvent is from 50:50 w/w to 70:30 w/w.
33. The method of claim 29, wherein said sustained release composition comprises:
a sucrose acetate isobutyrate to solvent ratio from 50:50 w/w to 85:15 w/w, wherein the sucrose acetate isobutyrate and solvent together form said liquid carrier;
a zinc to protein molar ratio from 100:1 to 1:1, wherein the zinc and protein together form said complex; and a liquid carrier to complex ratio from 95:5 w/v to 85:15 w/v.
a sucrose acetate isobutyrate to solvent ratio from 50:50 w/w to 85:15 w/w, wherein the sucrose acetate isobutyrate and solvent together form said liquid carrier;
a zinc to protein molar ratio from 100:1 to 1:1, wherein the zinc and protein together form said complex; and a liquid carrier to complex ratio from 95:5 w/v to 85:15 w/v.
34. The method of claim 33, wherein the ratio of sucrose acetate isobutyrate to solvent is from 50:50 w/w to 70:30 w/w.
35. The method of claim any one of claims 33-34, wherein the molar ratio of zinc to protein is from 10:1 to 1:1.
36. A kit, comprising:
a container;
a protein;
a polyol;
a metal cation; and a liquid carrier;
wherein the liquid carrier comprises sucrose acetate isobutyrate.
a container;
a protein;
a polyol;
a metal cation; and a liquid carrier;
wherein the liquid carrier comprises sucrose acetate isobutyrate.
37. The kit of claim 36, comprising a unit dosage of the protein.
38. The kit of any one of claims 36-37, wherein the polyol, the metal cation, and the liquid carrier are sterile.
39. The kit of any one of claims 36-38, further comprising a syringe.
40. The kit of any one of claims 36-39, wherein the container comprises a septum.
41. The kit of any one of claims 36-40, wherein the metal cation is divalent.
42. The kit of any one of claims 36-41, wherein the metal cation is zinc.
43. A composition, comprising:
a protein;
an alcohol; and a metal cation;
wherein said alcohol is selected from the group consisting of a monosaccharide, a polysaccharide, glycerol, mannitol, sorbitol, inositol, and polyethylene glycol.
a protein;
an alcohol; and a metal cation;
wherein said alcohol is selected from the group consisting of a monosaccharide, a polysaccharide, glycerol, mannitol, sorbitol, inositol, and polyethylene glycol.
44. The composition of claim 43, wherein said alcohol is selected from the group consisting of mannitol, threhalose, and polyethylene glycol.
45. The composition of any one of claims 43-44, wherein the mass ratio of alcohol to protein is from 100:1 to 1:100.
46. The composition of any one of claims 43-44, wherein the mass ratio of alcohol to protein is from 1:1 to 1:10.
47. The composition of any one of claims 43-46, wherein the metal cation is divalent.
48. The composition of any one of claims 43-47, wherein the metal cation is zinc.
49. The composition of claim 48, wherein the molar ratio of zinc to protein is from 1:1 to 100:1.
50. The composition of claim 48, wherein the molar ratio of zinc to protein is from 1:1 to 20:1.
51. The composition of claim 48, wherein the molar ratio of zinc to protein is from 1:1 to 10:1.
52. The composition of any one of claims 43-51, wherein the protein is selected from the group consisting of a growth hormone, insulin, and a growth factor.
53. The composition of any one of claims 43-52, further comprising a carrier material;
wherein the carrier material comprises a non-polymeric, non-water soluble liquid material having a viscosity of at least 5,000 cP at 37 °C
that does not crystallize neat under ambient physiological conditions.
wherein the carrier material comprises a non-polymeric, non-water soluble liquid material having a viscosity of at least 5,000 cP at 37 °C
that does not crystallize neat under ambient physiological conditions.
54. The composition of claim 53, wherein the liquid material is a stearate ester, a stearate amide, a long-chain fatty acid amide, a long-chain fatty alcohol, a long-chain ester, or a disaccharide ester.
55. The composition of claim 53, wherein the liquid material is acetylated sucrose distearate.
56. The composition of claim 53, wherein the liquid material is disaccharide acetate butyrate.
57. The composition of claim 53, wherein the liquid material is sucrose acetate isobutyrate.
58. The composition of any one of claims 43-57, wherein the composition has a viscosity less than 1000 cP at room temperature.
59. The composition of any one of claims 43-57, wherein the composition has a viscosity less than 200 cP at room temperature.
60. A method of administering a protein, comprising:
injecting the composition of any of claims 43-59 into a patient in need of said protein.
injecting the composition of any of claims 43-59 into a patient in need of said protein.
61. The method of claim 60, wherein less than 10% of the protein is released within 24 hours of administration.
62. The method of claim 60, wherein less than 0.2% of the protein is released within 24 hours of administration.
63. The method of any one of claims 60-62, wherein the percentage of the protein released within a 24 hour period is from 0.05% to 3%.
64. The method of any one of claims 60-62, wherein the percentage of the protein released within a 24 hour period is from 1% to 3%.
65. A method of making a sustained release composition, comprising:
mixing a complex and a liquid carrier to form said sustained release composition;
wherein said liquid carrier comprises sucrose acetate isobutyrate; and wherein said complex comprises a protein, an alcohol, and zinc;
wherein said alcohol is selected from the group consisting of a monosaccharide, a polysaccharide, glycerol, mannitol, sorbitol, inositol, and polyethylene glycol.
mixing a complex and a liquid carrier to form said sustained release composition;
wherein said liquid carrier comprises sucrose acetate isobutyrate; and wherein said complex comprises a protein, an alcohol, and zinc;
wherein said alcohol is selected from the group consisting of a monosaccharide, a polysaccharide, glycerol, mannitol, sorbitol, inositol, and polyethylene glycol.
66. The method of claim 65, wherein said sustained release composition has a viscosity less than 1000 cP at room temperature.
67. The method of claim 65, wherein said sustained release composition has a viscosity less than 200 cP at room temperature.
68. The method of any one of claims 65-67, wherein the molar ratio of zinc to protein is from 100:1 to 1:1.
69. The method of any one of claims 65-67, wherein the molar ratio of zinc to protein is from 10:1 to 1:1.
70. The method of any one of claims 65-69, wherein said liquid carrier further comprises a solvent.
71. The method of claim 70, wherein said solvent is ethanol, benzyl benzoate, miglyol, propylene carbonate, or benzyl alcohol.
72. The method of any one of claims 70-71, wherein the ratio of sucrose acetate isobutyrate to solvent is from 50:50 w/w to 85:15 w/w.
73. The method of any one of claims 70-71, wherein the ratio of sucrose acetate isobutyrate to solvent is from 50:50 w/w to 70:30 w/w.
74. The method of claim 70, wherein said sustained release composition comprises:
a sucrose acetate isobutyrate to solvent ratio from 50:50 w/w to 85:15 w/w, wherein the sucrose acetate isobutyrate and solvent together form said liquid carrier;
a zinc to protein molar ratio from 100:1 to 1:1, wherein the zinc and protein together form said complex; and a liquid carrier to complex ratio from 95:5 w/v to 85:15 w/v.
a sucrose acetate isobutyrate to solvent ratio from 50:50 w/w to 85:15 w/w, wherein the sucrose acetate isobutyrate and solvent together form said liquid carrier;
a zinc to protein molar ratio from 100:1 to 1:1, wherein the zinc and protein together form said complex; and a liquid carrier to complex ratio from 95:5 w/v to 85:15 w/v.
75. The method of claim 74, wherein the ratio of sucrose acetate isobutyrate to solvent is from 50:50 w/w to 70:30 w/w.
76. The method of claim any one of claims 74-75, wherein the molar ratio of zinc to protein is from 10:1 to 1:1.
77. A kit, comprising:
a container;
a protein;
an alcohol;
a metal cation; and a liquid carrier;
wherein the liquid carrier comprises sucrose acetate isobutyrate;
and wherein said alcohol is selected from the group consisting of a monosaccharide, a polysaccharide, glycerol, mannitol, sorbitol, inositol, and polyethylene glycol.
a container;
a protein;
an alcohol;
a metal cation; and a liquid carrier;
wherein the liquid carrier comprises sucrose acetate isobutyrate;
and wherein said alcohol is selected from the group consisting of a monosaccharide, a polysaccharide, glycerol, mannitol, sorbitol, inositol, and polyethylene glycol.
78. The kit of claim 77, comprising a unit dosage of the protein.
79. The kit of any one of claims 77-78, wherein the alcohol, the metal cation, and the liquid carrier are sterile.
80. The kit of any one of claims 77-79, further comprising a syringe.
81. The kit of any one of claims 77-80, wherein the container comprises a septum.
82. The kit of any one of claims 77-81, wherein the metal cation is divalent.
83. The kit of any one of claims 77-82, wherein the metal cation is zinc.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30027501P | 2001-06-21 | 2001-06-21 | |
US60/300,275 | 2001-06-21 | ||
US10/176,961 US7318931B2 (en) | 2001-06-21 | 2002-06-21 | Sustained release formulation |
PCT/US2002/019597 WO2003000282A1 (en) | 2001-06-21 | 2002-06-21 | Sustained release formulation |
US10/176,961 | 2002-06-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2448218A1 true CA2448218A1 (en) | 2003-01-03 |
CA2448218C CA2448218C (en) | 2012-05-29 |
Family
ID=26872798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2448218A Expired - Lifetime CA2448218C (en) | 2001-06-21 | 2002-06-21 | Sustained release formulation |
Country Status (10)
Country | Link |
---|---|
US (2) | US7318931B2 (en) |
EP (1) | EP1397155B1 (en) |
JP (2) | JP4460892B2 (en) |
AU (1) | AU2002320122B2 (en) |
CA (1) | CA2448218C (en) |
DK (1) | DK1397155T3 (en) |
ES (1) | ES2554106T3 (en) |
IL (1) | IL159048A0 (en) |
PT (1) | PT1397155E (en) |
WO (1) | WO2003000282A1 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7318931B2 (en) * | 2001-06-21 | 2008-01-15 | Genentech, Inc. | Sustained release formulation |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
US7160551B2 (en) * | 2002-07-09 | 2007-01-09 | The Board Of Trustees Of The University Of Illinois | Injectable system for controlled drug delivery |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
RU2005111253A (en) * | 2002-09-18 | 2005-11-20 | Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) | GHRH ANALOGUES |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
CA2507522C (en) | 2002-12-13 | 2015-02-24 | Durect Corporation | Oral drug delivery system |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
DE10312346A1 (en) * | 2003-03-20 | 2004-09-30 | Bayer Healthcare Ag | Controlled release system |
KR20060002922A (en) * | 2003-03-31 | 2006-01-09 | 알자 코포레이션 | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
ES2300758T3 (en) * | 2003-05-01 | 2008-06-16 | Ltt Bio-Pharma Co., Ltd. | COMPOSITION OF SUSTAINED RELEASE CONTAINING CINC, ITS PREPARATION AND PROCEDURE TO PRODUCE THE SAME. |
EP1708734A4 (en) * | 2004-01-07 | 2009-06-17 | Trimeris Inc | HIV gp41 HR2-DERIVED SYNTHETIC PEPTIDES, AND THEIR USE IN THERAPY TO INHIBIT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS |
US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
LT2767292T (en) * | 2004-09-17 | 2016-12-12 | Durect Corporation | Sustained Local Anesthetic Composition Containing SAIB |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
EP1912676A2 (en) * | 2005-07-28 | 2008-04-23 | (Osi) Eyetech, Inc. | Cyclitol linker polymer conjugate |
US7456251B2 (en) | 2006-02-02 | 2008-11-25 | Trimeris, Inc. | HIV fusion inhibitor peptides with improved biological properties |
CN101453982B (en) | 2006-05-30 | 2011-05-04 | 精达制药公司 | Two-piece, internal-channel osmotic delivery system flow modulator |
ES2422864T3 (en) | 2006-08-09 | 2013-09-16 | Intarcia Therapeutics, Inc | Osmotic release systems and piston units |
US8337883B2 (en) | 2006-11-03 | 2012-12-25 | Durect Corporation | Transdermal delivery systems |
AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
KR20100016142A (en) * | 2007-04-03 | 2010-02-12 | 트라이머리스, 인코퍼레이티드 | Novel formulations for delivery of antiviral peptide therapeutics |
RU2440097C2 (en) | 2007-04-23 | 2012-01-20 | Интарсия Терапьютикс, Инк. | Method of treating insulin-independent diabetes and obesity, osmotic delivery system and method for making it |
US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
CA2695697A1 (en) | 2007-08-07 | 2009-02-12 | Advanced Technologies And Regenerative Medicine, Llc | Protein formulations comprising gdf-5 in aqueous acidic solution |
MX2010003179A (en) * | 2007-09-25 | 2010-04-30 | Trimeris Inc | Methods of synthesis for therapeuthic anti-hiv peptides. |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
CA2706658A1 (en) | 2007-12-06 | 2009-06-18 | Durect Corporation | Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition |
CA2714506C (en) * | 2008-02-08 | 2016-06-07 | Qps Llc | Composition for sustained release delivery of proteins or peptides |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
AU2009236459B2 (en) | 2008-04-14 | 2013-07-25 | Advanced Technologies And Regenerative Medicine, Llc | Liquid buffered GDF-5 formulations |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
NZ592644A (en) * | 2008-11-28 | 2013-09-27 | Abbott Lab | Stable antibody compositions and methods for stabilizing same |
SG175188A1 (en) * | 2009-05-04 | 2011-11-28 | Abbott Biotech Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
EP3323423B1 (en) | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
US20110229457A1 (en) * | 2010-03-12 | 2011-09-22 | Surmodics, Inc. | Injectable drug delivery system |
MX2013001858A (en) | 2010-08-18 | 2013-09-13 | Del Mar Pharmaceuticals | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol. |
RU2015154965A (en) | 2010-11-11 | 2019-01-16 | Эббви Байотекнолоджи Лтд. | IMPROVED HIGH-CONCENTRATED LIQUID PRODUCTS ANTIBODIES AGAINST TNF ALPHA |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
EP2758043A4 (en) | 2011-08-17 | 2016-02-24 | Dennis M Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol |
KR102276161B1 (en) | 2011-10-25 | 2021-07-14 | 프로테나 바이오사이언시즈 리미티드 | Antibody formulations and methods |
EP2804602A4 (en) | 2012-01-20 | 2016-08-10 | Dennis Brown | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma |
WO2013142817A2 (en) | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
WO2013169600A1 (en) | 2012-05-09 | 2013-11-14 | Delmar Pharmaceuticals | Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies |
AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
CN105120659A (en) | 2013-03-15 | 2015-12-02 | 度瑞公司 | Compositions with a rheological modifier to reduce dissolution variability |
AU2014251038A1 (en) | 2013-04-08 | 2015-11-26 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
CA2928568A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
WO2015058868A1 (en) | 2013-10-25 | 2015-04-30 | Pangaea Biotech, S.L. | Compositions and methods for the treatment of cancer |
US20160303242A1 (en) | 2013-12-09 | 2016-10-20 | Durect Corporation | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same |
WO2016020901A1 (en) | 2014-08-07 | 2016-02-11 | Acerta Pharma B.V. | Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
EP3302354B1 (en) | 2015-06-03 | 2023-10-04 | i2o Therapeutics, Inc. | Implant placement systems |
WO2017200943A1 (en) | 2016-05-16 | 2017-11-23 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
KR20190104039A (en) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs |
CA3167217A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1456433A (en) * | 1973-06-25 | 1976-11-24 | Quaker Oats Co | Semi-moist cat food |
US4016273A (en) | 1975-07-16 | 1977-04-05 | American Cyanamid Company | Sustained release forms of certain oxazepines for parenteral administration |
DE2916711A1 (en) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blood coagulation factors and process for their manufacture |
US5411951A (en) | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
IL79681A (en) * | 1985-08-12 | 1991-06-10 | Int Minerals & Chem Corp | Transition metal complexes of growth hormones and their prolonged release compositions |
JPS62257990A (en) | 1986-05-02 | 1987-11-10 | 花王株式会社 | Production of enzyme granule for detergent |
WO1989003671A1 (en) | 1987-10-29 | 1989-05-05 | Dainippon Pharmaceutical Co., Ltd. | Sustained-release preparation |
US5096885A (en) | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
JPH0223866A (en) | 1988-07-11 | 1990-01-26 | Kikkoman Corp | Stabilization of sucrose phosphorylase |
FR2634121B1 (en) | 1988-07-13 | 1992-05-07 | Imedex | PROCESS FOR THE PREPARATION OF COLLAGEN MICROPARTICLES AND PRODUCTS OBTAINED |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5324520A (en) | 1988-12-19 | 1994-06-28 | Vipont Pharmaceutical, Inc. | Intragingival delivery systems for treatment of periodontal disease |
US4975271A (en) | 1988-12-19 | 1990-12-04 | Vipont Pharmaceutical, Inc. | Muscosal delivery systems for treatment of periodontal disease |
US5114929A (en) | 1989-03-21 | 1992-05-19 | Beecham Group P.L.C. | Pharmaceutical formulation |
US5776963A (en) | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US5077049A (en) | 1989-07-24 | 1991-12-31 | Vipont Pharmaceutical, Inc. | Biodegradable system for regenerating the periodontium |
SE465950B (en) | 1989-10-23 | 1991-11-25 | Medinvent Sa | Combination of an aggregate particle size, crystalline or freeze-dried drug with a pseudoplastic gel for preparation of an injectable preparation as well as a process for its preparation |
US5133981A (en) | 1989-11-17 | 1992-07-28 | Atrix Laboratories, Inc. | Purification of benzophenanthridine alkaloids extracts from alkaloid extracts |
PT99345A (en) | 1990-10-30 | 1992-09-30 | Alza Corp | PROCESS FOR THE PREPARATION OF APPROPRIATE SYSTEMS FOR THE LIBERATION OF THERAPEUTIC AGENTS |
JPH04271785A (en) | 1991-02-28 | 1992-09-28 | Kao Corp | Enzymic solid pharmaceutical and its production |
US5416071A (en) | 1991-03-12 | 1995-05-16 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release containing epo and hyaluronic acid |
AU1757092A (en) | 1991-03-28 | 1992-11-02 | Genentech Inc. | Stable growth hormone metal ion formulations |
US5252338A (en) | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5711968A (en) | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5242910A (en) | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
EP0674506B1 (en) | 1992-12-02 | 2000-08-23 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
PT686045E (en) * | 1993-02-23 | 2001-04-30 | Genentech Inc | STABILIZATION BY EXPIPIENTS OF POLYPEPTIDES TREATED WITH ORGANIC SOLVENTS |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
NZ260909A (en) | 1993-07-05 | 1995-04-27 | Takeda Chemical Industries Ltd | Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution |
US6080429A (en) | 1993-10-25 | 2000-06-27 | Genentech, Inc. | Method for drying microspheres |
JP3125610B2 (en) | 1993-12-24 | 2001-01-22 | 和光純薬工業株式会社 | Method for stabilizing L-methionine γ-lyase |
ATE178789T1 (en) | 1994-02-21 | 1999-04-15 | Takeda Chemical Industries Ltd | POLYESTER MATRIX FOR A DELAYED RELEASE PHARMACEUTICAL COMPOSITION |
US5556905A (en) | 1994-03-30 | 1996-09-17 | Reilly Industries, Inc. | Physically-modified degradable thermoplastic compositions |
JP4259610B2 (en) | 1994-04-08 | 2009-04-30 | キューエルティー・ユーエスエイ・インコーポレーテッド | Liquid delivery composition |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US6004549A (en) | 1994-12-14 | 1999-12-21 | Schering Corporation | Crystalline protein controlled release compositions |
JP2001515457A (en) | 1995-06-07 | 2001-09-18 | アルカームズ コントロールド セラピューティックス,インコーポレイテッド | Aggregation-stabilized bioactive substance release device |
US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
SK281571B6 (en) | 1995-06-07 | 2001-05-10 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
US5747058A (en) * | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
BRPI9609033B8 (en) | 1995-06-07 | 2017-04-04 | Durect Corp | composition and emulsion for the controlled release of a substance. |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
CA2192773C (en) | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Production of sustained-release preparation for injection |
US5792477A (en) | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
US5981489A (en) | 1996-07-18 | 1999-11-09 | Alza Corporation | Non-aqueous protic peptide formulations |
US5851229A (en) | 1996-09-13 | 1998-12-22 | Meadox Medicals, Inc. | Bioresorbable sealants for porous vascular grafts |
ATE272394T1 (en) | 1996-10-31 | 2004-08-15 | Takeda Chemical Industries Ltd | DELAYED RELEASE PREPARATION |
ES2158611T3 (en) | 1996-12-20 | 2001-09-01 | Alza Corp | COMPOSITION IN INJECTABLE GEL WITH RETARD EFFECT AND PROCEDURE FOR THE PREPARATION OF SUCH COMPOSITION. |
ZA9711385B (en) | 1996-12-20 | 1999-06-18 | Takeda Chemical Industries Ltd | Method of producing a sustained-release preparation |
US6051558A (en) | 1997-05-28 | 2000-04-18 | Southern Biosystems, Inc. | Compositions suitable for controlled release of the hormone GnRH and its analogs |
US6113947A (en) | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6191107B1 (en) | 1997-09-26 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Complex of human growth hormone and zinc |
JPH11158200A (en) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | Human growth hormone/zinc complex and its use |
US6039977A (en) | 1997-12-09 | 2000-03-21 | Alza Corporation | Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods |
CN1173742C (en) | 1997-12-26 | 2004-11-03 | 山之内制药株式会社 | Sustained release medicinal compositions |
DE19813010A1 (en) | 1998-03-25 | 1999-10-14 | Aventis Res & Tech Gmbh & Co | Delayed release microcapsules |
US6174547B1 (en) | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
CN1158068C (en) * | 1998-12-23 | 2004-07-21 | 安姆根有限公司 | Polyol/oil suspensions for the sustained release of proteins |
ES2207123T3 (en) | 1999-06-14 | 2004-05-16 | Baxter International Inc. | MICROSPHERAS OF SUSTAINED LIBERATION. |
WO2000078335A1 (en) * | 1999-06-18 | 2000-12-28 | Southern Biosystems, Inc. | COMPOSITIONS FOR CONTROLLED RELEASE OF THE HORMONE GnRH AND ITS ANALOGS |
US6245806B1 (en) * | 1999-08-03 | 2001-06-12 | Merck & Co., Inc. | HIV integrase inhibitors |
US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
EP1274459B1 (en) | 2000-04-19 | 2005-11-16 | Genentech, Inc. | Sustained release formulations comprising growth hormone |
AU2001271491A1 (en) | 2000-06-26 | 2002-01-08 | Monsanto Technology Llc | Non-aqueous surfactant-containing formulations for extended release of somatotropin |
US7318931B2 (en) | 2001-06-21 | 2008-01-15 | Genentech, Inc. | Sustained release formulation |
GB2403086B (en) | 2003-06-17 | 2005-07-20 | Motorola Inc | Cartesian loop transmitter and method of adjusting an output level of such transmitter |
CN105709221B (en) * | 2011-04-06 | 2020-11-17 | 拜欧瓦克西姆有限公司 | Pharmaceutical composition for the prevention and/or treatment of HIV diseases in humans |
-
2002
- 2002-06-21 US US10/176,961 patent/US7318931B2/en not_active Expired - Lifetime
- 2002-06-21 EP EP02749622.3A patent/EP1397155B1/en not_active Expired - Lifetime
- 2002-06-21 ES ES02749622.3T patent/ES2554106T3/en not_active Expired - Lifetime
- 2002-06-21 DK DK02749622.3T patent/DK1397155T3/en active
- 2002-06-21 JP JP2003506926A patent/JP4460892B2/en not_active Expired - Lifetime
- 2002-06-21 IL IL15904802A patent/IL159048A0/en active IP Right Grant
- 2002-06-21 PT PT2749622T patent/PT1397155E/en unknown
- 2002-06-21 AU AU2002320122A patent/AU2002320122B2/en not_active Expired
- 2002-06-21 CA CA2448218A patent/CA2448218C/en not_active Expired - Lifetime
- 2002-06-21 WO PCT/US2002/019597 patent/WO2003000282A1/en active IP Right Grant
-
2007
- 2007-12-12 US US11/954,608 patent/US8067020B2/en not_active Expired - Fee Related
-
2009
- 2009-08-26 JP JP2009195264A patent/JP2010013456A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US8067020B2 (en) | 2011-11-29 |
US20030045454A1 (en) | 2003-03-06 |
EP1397155B1 (en) | 2015-09-30 |
US20080090754A1 (en) | 2008-04-17 |
ES2554106T3 (en) | 2015-12-16 |
AU2002320122B2 (en) | 2007-07-26 |
IL159048A0 (en) | 2004-05-12 |
JP4460892B2 (en) | 2010-05-12 |
WO2003000282A1 (en) | 2003-01-03 |
JP2010013456A (en) | 2010-01-21 |
DK1397155T3 (en) | 2015-12-07 |
PT1397155E (en) | 2015-12-07 |
EP1397155A1 (en) | 2004-03-17 |
US7318931B2 (en) | 2008-01-15 |
JP2005508299A (en) | 2005-03-31 |
CA2448218C (en) | 2012-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2448218A1 (en) | Sustained release formulation | |
EP1173151B1 (en) | Dry, mouldable drug formulation | |
EP2067468A1 (en) | Sustained release dosage forms of anesthetics for pain management | |
AU695622B2 (en) | A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof | |
US6352722B1 (en) | Derivatized carbohydrates, compositions comprised thereof and methods of use thereof | |
CA2801676C (en) | Compositions | |
US10198218B2 (en) | Injectable flowable composition comprising buprenorphine | |
WO2005009408B1 (en) | Sustained release dosage forms of anesthetics for pain management | |
EP0633907A1 (en) | Additives for bioerodible polymers to regulate degradation | |
HU228386B1 (en) | Polymeric delivery formulations of leuprolide with improved efficacy | |
JP2004500423A5 (en) | ||
CN104248623A (en) | Sustained release formulations using non-aqueous carriers | |
US20130203796A1 (en) | Injectable flowable composition comprising buprenorphine | |
CN102711728A (en) | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs | |
US20080300322A1 (en) | Delivery vehicles containing rosin resins | |
CN1362883A (en) | Stable composition comprising epidermal growth factor as active ingredient | |
CA2989283A1 (en) | Long acting liraglutide compositions | |
US20120082709A1 (en) | Compositions and methods for delivery of materials | |
CN103536529A (en) | Ceftiofur-containing long-acting injection and preparation method | |
US20200261584A1 (en) | Stabilized protein gel preparation | |
EP1023908A2 (en) | Medical composition of hydroxy acid-based oligomer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20220621 |
|
MKEX | Expiry |
Effective date: 20220621 |